Tracy Todd Batchelor, M.D.
Co-Author
This page shows the publications co-authored by Tracy Batchelor and David Reardon.
Connection Strength
1.178
-
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
Score: 0.219
-
Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9.
Score: 0.149
-
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013.
Score: 0.131
-
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53.
Score: 0.094
-
Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2021 Dec 08.
Score: 0.061
-
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
Score: 0.056
-
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
Score: 0.054
-
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
Score: 0.052
-
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
Score: 0.050
-
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
Score: 0.048
-
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
Score: 0.048
-
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
Score: 0.044
-
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
Score: 0.038
-
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
Score: 0.038
-
Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
Score: 0.036
-
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
Score: 0.030
-
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.